Mani Mohindru Sells 16,041 Shares of Cara Therapeutics Inc (CARA) Stock

Cara Therapeutics Inc (NASDAQ:CARA) CFO Mani Mohindru sold 16,041 shares of Cara Therapeutics stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $19.12, for a total value of $306,703.92. Following the sale, the chief financial officer now owns 24,067 shares in the company, valued at $460,161.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mani Mohindru also recently made the following trade(s):

  • On Friday, December 28th, Mani Mohindru sold 4,500 shares of Cara Therapeutics stock. The stock was sold at an average price of $12.55, for a total value of $56,475.00.
  • On Friday, December 28th, Mani Mohindru sold 4,500 shares of Cara Therapeutics stock. The stock was sold at an average price of $12.55, for a total value of $56,475.00.

Shares of CARA opened at $18.37 on Friday. Cara Therapeutics Inc has a fifty-two week low of $11.46 and a fifty-two week high of $24.30. The stock has a market capitalization of $721.76 million, a P/E ratio of -8.92 and a beta of 2.68.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.07. The firm had revenue of $5.53 million during the quarter, compared to analysts’ expectations of $3.35 million. As a group, analysts forecast that Cara Therapeutics Inc will post -2.31 earnings per share for the current year.

A number of research firms have recently commented on CARA. Zacks Investment Research cut Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 21st. Laidlaw set a $30.00 target price on Cara Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 20th. Canaccord Genuity set a $25.00 target price on Cara Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 20th. BidaskClub upgraded Cara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 12th. Finally, HC Wainwright set a $30.00 price objective on Cara Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $24.03.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Avondale Wealth Management increased its holdings in Cara Therapeutics by 50.0% in the 4th quarter. Avondale Wealth Management now owns 3,000 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Cara Therapeutics by 36.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,601 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 964 shares during the last quarter. Captrust Financial Advisors increased its holdings in Cara Therapeutics by 40.0% in the 4th quarter. Captrust Financial Advisors now owns 4,900 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 1,400 shares during the last quarter. Legal & General Group Plc increased its holdings in Cara Therapeutics by 36.2% in the 3rd quarter. Legal & General Group Plc now owns 5,538 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 1,472 shares during the last quarter. Finally, Pacer Advisors Inc. purchased a new position in Cara Therapeutics during the 3rd quarter valued at about $138,000. 61.72% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Mani Mohindru Sells 16,041 Shares of Cara Therapeutics Inc (CARA) Stock” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://transcriptdaily.com/2019/03/17/mani-mohindru-sells-16041-shares-of-cara-therapeutics-inc-cara-stock.html.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Recommended Story: Trading Stocks – What are percentage gainers?

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.